Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy.

Acta Pharm Sin B. 2019; 
GuoQin,LiChao,ZhouWenxi,ChenXinli,ZhangYu,LuYifei,ZhangYujie,ChenQinjun,LiangDonghui,SunTao,Jiang
Products/Services Used Details Operation
Catalog Antibody The T7promoter (TAATACGACTCACTATAGGGAT) and the linear DNA with anti-miR21 sequence (ATAGTGAGTCGTATTAACGTACCAACTAGCTTATCAGACTGATGTTGACTTGCAACATCAGT CCTCCCAGCTATAGAGGCATATCCCT) were obtained from Genscript Biotechnology Company (Nanjing, China). Get A Quote

摘要

Oncogenic microRNAs are essential components in regulating the gene expression of cancer cells. Especially miR21, which is a major player involved of tumor initiation, progression, invasion and metastasis in several cancers. The delivery of anti-miR21 sequences has significant potential for cancer treatment. Nevertheless, since anti-miR21 sequences are extremely unstable and they need to obtain certain concentration to function, it is intensely difficult to build an effective delivery system for them. The purpose of this work is to construct a self-assembled glutathione (GSH)-responsive system with tumor accumulation capacity for effective anti-miR21 delivery and cancer therapy. A novel drug delivery ... More

关键词

Cancer treatment,Dehydroascorbic acid,MiRNA21,Nanomedicine,RNAi nanoparticle,Rolling circle transcription,Self-assembly,Tumor-targe
XML 地图